|
1
|
Matsuda T, Marugame T, Kamo KI, Katanoda
K, Ajiki W and Sobue T; The Japan Cancer Surveillance Research
Group. Cancer incidence and incidence rates in Japan in 2006: based
on data from 15 population-based cancer registries in the
monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin
Oncol. 42:139–147. 2012. View Article : Google Scholar
|
|
2
|
Matsuda T, Marugame T, Kamo K, Katanoda K,
Ajiki W and Sobue T: Cancer incidence and incidence rates in Japan
in 2005: based on data from 12 population-based cancer registries
in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn
J Clin Oncol. 41:139–147. 2011. View Article : Google Scholar
|
|
3
|
Amant F, Van Calsteren K, Vergote I and
Ottevanger N: Gynecologic oncology in pregnancy. Crit Rev Oncol
Hematol. 67:187–195. 2008. View Article : Google Scholar
|
|
4
|
Fleming GF, Brunetto VL and Cella D: Phase
III trial of doxorubicin plus cisplatin with or without paclitaxel
plus filgrastim in advanced endometrial carcinoma: a Gynecologic
Oncology Group study. Jpn J Clin Oncol. 22:2159–2166. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soslow RA, Bissonnette JP, Wilton A,
Ferguson SE, Alektiar KM and Duska LR: Clinicopathologic analysis
of 187 high-grade endometrial carcinomas of different histologic
subtypes: similar outcomes belie distinctive biologic differences.
Am J Surg Pathol. 31:979–987. 2007. View Article : Google Scholar
|
|
6
|
Hamilton CA, Cheung MK, Osann K, Balzer B,
Berman ML and Husain A: The effect of adjuvant chemotherapy versus
whole abdominopelvic radiation on the survival of patients with
advanced stage uterine papillary serous carcinoma. Gynecol Oncol.
103:679–683. 2006. View Article : Google Scholar
|
|
7
|
Kelly MG, O’Malley DM, Hui P, et al:
Improved survival in surgical stage I patients with uterine
papillary serous carcinoma (UPSC) treated with adjuvant
platinum-based chemotherapy. Gynecol Oncol. 98:353–359. 2005.
View Article : Google Scholar
|
|
8
|
Zanotti KM, Belinson JL, Kennedy AW,
Webster KD and Markman M: The use of paclitaxel and platinum-based
chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol.
74:272–277. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alexander IF, Shine J and Sutherland RL:
Progestin regulation of estrogen receptor messenger RNA in human
breast cancer cells. Mol Endocrinol. 4:821–828. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kashima H, Horiuchi A, Uchikawa J,
Miyamoto T, Suzuki A, Ashida T, Konishi I and Shiozawa T:
Up-regulation of nuclear receptor corepressor (NCoR) in
progestin-induced growth suppression of endometrial hyperplasia and
carcinoma. Anticancer Res. 29:1023–1029. 2009.PubMed/NCBI
|
|
11
|
Miyamoto T, Horiuchi A, Kashima H, Suzuki
A, Yamada T, Kurai M, Konishi I and Shiozawa T: Inverse correlation
between Skp2 and p27(Kip1) in normal endometrium and endometrial
carcinoma. Gynecol Endocrinol. 26:220–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Banno K, Kisu I, Yanokura M, et al:
Progestin therapy for endometrial cancer: the potential of
fourth-generation progestin (Review). Int J Oncol. 40:1755–1762.
2012.PubMed/NCBI
|
|
13
|
Katsuki Y, Shibutani Y, Aoki D and Nozawa
S: Dienogest, a novel synthetic steroid, overcomes
hormone-dependent cancer in a different manner than progestins.
Cancer. 79:169–176. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakamura M, Katsuki Y, Shibutani Y and
Oikawa T: Dienogest, a synthetic steroid, suppresses both embryonic
and tumor-cell-induced angiogenesis. Eur J Pharmacol. 386:33–40.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katayama H, Katayama T, Uematsu K,
Hiratsuka M, Kiyomura M, Shimizu Y, Sugita A and Ito M: Effect of
dienogest administration on angiogenesis and hemodynamics in a rat
endometrial autograft model. Hum Reprod. 25:2851–2858. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gerlinger C, Faustmann T, Hassal JJ and
Seitz C: Treatment of endometriosis in different ethnic
populations: a meta-analysis of two clinical trials. BMC Womens
Health. 12:92012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Foster RH and Wilde MI: Dienogest. Drugs.
56:825–833. 1998. View Article : Google Scholar
|
|
18
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiralerspong S, Palla SL, Giordano SH, et
al: Metformin and pathologic complete responses to neoadjuvant
chemotherapy in diabetic patients with breast cancer. J Clin Oncol.
27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y
and Liao QP: Metformin promotes progesterone receptor expression
via inhibition of mammalian target of rapamycin (mTOR) in
endometrial cancer cells. J Steroid Biochem Mol Biol. 126:113–120.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsuji K, Kisu I, Banno K, et al:
Metformin: a possible drug for treatment of endometrial cancer.
OJOG. 2:1–6. 2012. View Article : Google Scholar
|
|
22
|
Bednar F and Simeone DM: Metformin and
cancer stem cells: old drug, new targets. Cancer Prev Res.
5:351–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang S and Houghton PJ: Targeting mTOR
signaling for cancer therapy. Curr Opin Pharmacol. 3:371–377. 2003.
View Article : Google Scholar
|
|
24
|
Dedes KJ, Wetterskog D, Ashworth A, Kaye
SB and Reis-Filho JS: Emerging therapeutic targets in endometrial
cancer. Nat Rev Clin Oncol. 8:261–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oda K, Shoji K, Nakagawa S, et al:
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor,
NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial
carcinomas. PLoS One. 29:e374312012.PubMed/NCBI
|
|
26
|
Colombo N, McMeekin S, Schwartz P, et al:
A phase II trial of the mTOR inhibitor AP23573 as a single agent in
advanced endometrial cancer. J Clin Oncol. 25:55162007.
|
|
27
|
Slomovitz BM, Lu KH, Johnston T, et al: A
phase 2 study of the oral mammalian target of rapamycin inhibitor,
everolimus, in patients with recurrent endometrial carcinoma.
Cancer. 116:5415–5419. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oza AM, Elit L, Biagi J, et al: Molecular
correlates associated with a phase II study of temsirolimus
(CCI-779) in patients with metastatic or recurrent endometrial
cancer-NCIC IND 160. J Clin Oncol. 24:30032004.
|
|
29
|
Oza A, Elit L, Provencher D, et al: A
phase II study of temsirolimus (CCI-779) in patients with
metastatic and/or locally advanced recurrent endometrial cancer
previously treated with chemotherapy: NCIC CTG IND 160b. J Clin
Oncol. 26:55162008.
|
|
30
|
Banno K, Kisu I, Yanokura M, Masuda K,
Ueki A, Kobayashi Y, Susumu N and Aoki D: Epigenetics and genetics
in endometrial cancer: new carcinogenic mechanisms and relationship
with clinical practice. Epigenomics. 4:147–162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kawaguchi M, Banno K, Yanokura M, et al:
Analysis of candidate target genes for mononucleotide repeat
mutation in microsatellite instability-high (MSI-H) endometrial
cancer. Int J Oncol. 35:977–982. 2009.PubMed/NCBI
|
|
32
|
Boren T, Xiong Y, Hakam A, et al:
MicroRNAs and their target messenger RNAs associated with
endometrial carcinogenesis. Gynecol Oncol. 110:206–215. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsuruta T, Kozaki K, Uesugi A, et al:
miR-152 is a tumor suppressor microRNA that is silenced by DNA
hypermethylation in endometrial cancer. Cancer Res. 20:6450–6462.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takai N, Desmond JC, Kumagai T, Gui D,
Said JW, Whittaker S, Miyakawa I and Koeffler HP: Histone
deacetylase inhibitors have a profound antigrowth activity in
endometrial cancer cells. Clin Cancer Res. 10:1141–1149. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Takai N, Ueda T, Nishida M, Nasu K,
Matsuda K, Kusumoto M and Narahara H: CBHA is a family of hybrid
polar compounds that inhibit histone deacetylase, and induces
growth inhibition, cell cycle arrest and apoptosis in human
endometrial and ovarian cancer cells. Oncology. 70:97–105. 2006.
View Article : Google Scholar
|
|
36
|
Ueda T, Takai N, Nishida M, Nasu K and
Narahara H: Apicidin, a novel histone deacetylase inhibitor, has
profound anti-growth activity in human endometrial and ovarian
cancer cells. Int J Mol Med. 19:301–308. 2007.PubMed/NCBI
|
|
37
|
Kato K, Kuhara A, Yoneda T, et al: Sodium
butyrate inhibits the self-renewal capacity of endometrial tumor
side-population cells by inducing a DNA damage response. Mol Cancer
Ther. 10:1430–1439. 2011. View Article : Google Scholar
|
